Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas

D Freihoff1, A Kempe1, B Beste1, B Wappenschmidt1, E Kreyer1, Y Hayashi2, A Meindl3, D Krebs1, OD Wiestler2, A von Deimling2 and RK Schmutzler1,2

1Department of Obstetrics and Gynecology, University of Bonn Medical Center, D-53105 Bonn, Germany; 2Department of Neuropathology, University of Bonn Medical Center, D-53105 Bonn, Germany; 3Department of Medical Genetics, Ludwig Maximilian University, D-80336 Munich, Germany

Summary PTEN is a novel tumour-suppressor gene located on chromosomal band 10q23.3. This region displays frequent loss of heterozygosity (LOH) in a variety of human neoplasms including breast carcinomas. The detection of PTEN mutations in Cowden disease and in breast carcinoma cell lines suggests that PTEN may be involved in mammary carcinogenesis. We here report a mutational analysis of tumour specimens from 103 primary breast carcinomas and constitutive DNA from 25 breast cancer families. The entire coding region of PTEN was screened by single-strand conformation polymorphism (SSCP) analysis and direct sequencing using intron-based primers. No germline mutations could be identified in the breast cancer families and only one sporadic carcinoma carried a PTEN mutation at one allele. In addition, all sporadic tumours were analysed for homozygous deletions by differential polymerase chain reaction (PCR) and for allelic loss using the microsatellite markers D10S215, D10S564 and D10S573. No homozygous deletions were detected and only 10 out of 94 informative tumours showed allelic loss in the PTEN region. These results suggest that PTEN does not play a major role in breast cancer formation.

Keywords: PTEN/MMAC1/TEP1; breast cancer; mutations; LOH10q; tumour-suppressor gene

Breast carcinoma represents the most common malignancy of women in Western countries. Despite its prevalence, the molecular mechanisms of breast cancer formation and progression are still poorly understood. Molecular studies suggest that tumour-suppressor genes involved in hereditary tumour formation may also be altered in their sporadic counterparts (Fearon, 1997). Five per cent of all patients with breast carcinomas report a family history and the majority of these familial cases have been associated with germline mutations of the BRCA1 or BRCA2 tumour-suppressor genes (Miki et al, 1994; Wooster et al, 1995). However, the BRCA1 and BRCA2 genes are not usually altered in sporadic breast carcinomas (Lancaster et al, 1996; Miki et al, 1996), although loss of heterozygosity (LOH) in the BRCA1 and BRCA2 on chromosomal arms 17q and 13q is frequently observed (Schmutzler et al, 1997).

Recently, the PTEN/MMAC1/TEP1 tumour-suppressor gene has been identified on chromosomal band 10q23.3 (Li and Sun, 1997; Li et al, 1997; Steck et al, 1997). The product of this gene harbours a tyrosine phosphatase domain which shares high sequence homology with the cytoskeleton proteins tensin and auxilin. Mutations of PTEN were observed in a variety of tumours including breast carcinoma cell lines and primary invasive breast carcinomas (Li et al, 1997; Steck et al, 1997). These mutations included homozygous deletions and frameshift or nonsense mutations. Moreover, loss of heterozygosity affecting 10q23.3 was detected in as many as 50% of primary breast carcinomas. Germline mutations of PTEN have been identified in Cowden disease, a rare autosomal dominant cancer syndrome characterized by malignancies of the breast, thyroid and brain (Liaw et al, 1997). These observations point to PTEN as an interesting candidate for a tumour-suppressor gene associated with breast cancer.

Recent studies on sporadic tumours demonstrated that mutations in the PTEN gene are frequent events in glioblastomas, malignant melanomas and endometrial carcinomas of the endometrioid type (Guldberg et al, 1997; Kong et al, 1997; Rasheed et al, 1997; Tashiro et al, 1997; Wang et al, 1997). In endometrial carcinomas, PTEN mutations were predominantly found in tumours with microsatellite instability (Kong et al, 1997; Tashiro et al, 1997). It remains to be shown whether the association of PTEN mutations and microsatellite instability is of biological significance. In a series of 54 sporadic breast carcinomas, two deletions resulting in truncated proteins and various missense mutations of unknown significance have been reported (Rhei et al, 1997). To further elucidate the potential role of PTEN in breast carcinomas, we analysed 103 sporadic breast carcinomas for mutations, homozygous deletions and loss of heterozygosity, and 25 families with hereditary breast cancer for constitutive mutations in the PTEN gene.

MATERIALS AND METHODS

Tumour specimens from sporadic breast carcinomas and blood samples from patients with hereditary breast carcinomas

Breast cancer families were recruited at the University Hospital Bonn and the Department of Medical Genetics, University of Munich, Germany. Our series comprised 25 families fulfilling the following criteria: (1) at least two affected female relatives with breast or ovarian cancer and at least one patient with age at manifestation of less than 50 years; (2) one affected female with two
cancers, either bilateral breast cancer or breast and ovarian cancer; (3) one affected female with an age of onset for breast cancer under 35 years. Male breast cancer did not occur in these families. Most of the families were high-risk families with at least three breast or ovarian carcinomas (Table 1). BRCA1 mutations were excluded in all families by complete sequencing of the coding region including exon/intron boundaries. BRCA2 mutation analysis is currently under investigation and so far excluded by single-strand conformation polymorphism (SSCP) analysis in five families. In addition, in ten families frequent mutations in the BRCA2 gene could be excluded by direct sequencing of exons 9, 23 and 27.

Tissue was obtained from 103 women undergoing surgery for sporadic breast carcinomas at the University Hospital Bonn, the St. Elisabeth Hospital Bonn-Bad Godesberg and the Marienhospital Bruehl, Germany. Malignant tumours were grouped according to the UICC TNM (Spieß et al, 1990) classification. The WHO classification was used for histopathological analysis (World Health Organization, 1981). Histological grading was performed according to Bloom and Richardson (1957). The oestrogen and progesterone receptor (ER and PR) status were determined by the dextran-coated charcoal (DCC) method or by a monoclonal antibody assay (Remmele et al, 1986). Thirteen of the carcinomas represented recurrent or metastatic tumours, 88 primary carcinomas, and from two no data were available. Among the primary carcinomas, 36 corresponded to pT1 and 40 were larger tumours (pT > 1). From 12 tumours, no data were available. Forty-nine tumours were classified as pN0, 38 were characterized by lymph node infiltration, and from one tumour no staging data was available. Sixty-seven carcinomas were histopathologically classified as ductal carcinomas, nine as lobular carcinoma, two as medullary carcinoma, two as mucinous carcinomas, one as tubular carcinoma and three as ductal carcinoma in situ. From four tumours, no histological subclassification was obtained. Twenty-four carcinomas were classified as grade III, 59 tumours as grade II or I, and from five tumours grading was not available. Seventeen tumours were ER negative and 66 ER positive. PR expression was detected in 50 tumours and undetectable in 33 tumours. For five carcinomas, the hormone receptor status was not available.

Tissue samples were stored at −80°C and blood samples at −20°C until further treatment. Tissue sample was processed by microdissection to exclude regions of normal breast tissue and only samples containing more than 90% tumour cells were investigated. DNA was extracted from tissue and peripheral leucocytes using a conventional phenol–chloroform protocol.

### SSCP analysis and DNA sequencing

For a mutational analysis of the PTEN gene, intronic and overlapping exonic primers were used for amplification (Duerr et al, 1998). The primers cover the entire coding sequence as well as the exon/intron boundaries of the PTEN gene. Polymerase chain reaction (PCR) was performed in a volume of 10 μl containing 20 ng of DNA, 50 mM potassium chloride, 10 mM tris-HCl, 200 μM each dNTP, 0.1% gelatin, 10 pmol of each primer, 1.0–2.0 mM magnesium chloride and 0.25 U Taq polymerase. Initial denaturation at 94°C for 3 min was followed by 30 cycles on an automated thermal cycler (Hybaid, Omnigene, USA). Denaturation at 94°C for 30 s was followed by annealing at 50–55°C for 40 s and extension at 72°C for 40 s. A final extension step at 72°C for 10 min was added. Single-strand conformation polymorphism (SSCP) analysis was carried out on a sequencing apparatus (Pokerface II,

---

**Table 1** Characteristics of the families analysed for PTEN mutations

|                  | Number of cases per family | Number of families | BRCA1 Mutation analysis | BRCA2 Mutation analysis |
|------------------|---------------------------|--------------------|-------------------------|-------------------------|
| **Breast cancer only** |                           |                    |                         |                         |
| 1*               | 2                         | All neg.           | All neg. for f.m.       |                         |
| 2                | 4                         | All neg.           | All neg. for f.m.       |                         |
| 3                | 7                         | All neg.           | 3 fam. neg.             |                         |
| ≥4               | 6                         | All neg.           | 1 fam. neg. for f.m.    |                         |
| **Breast and ovarian cancer** |                       |                    |                         |                         |
| 3                | 1                         | All neg.           | All neg. for f.m.       |                         |
| ≥4               | 5                         | All neg.           | 2 fam. neg. for f.m.    |                         |

Clinical characteristics of the analysed families (fam.) at risk for breast and/or ovarian cancer. *In the two families with one case of breast cancer only, ages at manifestation were 33 and 34 years. All families were negative (neg.) for BRCA1 mutations. BRCA2 mutations could be excluded in five families. Additionally, ten families were tested negative for frequent BRCA2 mutations (f.m.) in the exons 9, 23 and 27.

© Cancer Research Campaign 1999 British Journal of Cancer (1999) 79(5/6), 754–758
Hoefer, San Francisco, USA) using 10% acrylamide gels with a bisacrylamide:acylamide ratio of 1:59 or 12% acrylamide gels with a bisacrylamide:acylamide ratio of 1:29 and 1:79, electrophoresis at 5–10 W and variable temperatures for 14 h. Silver staining of the gels was performed as previously described (von Deimling et al, 1993; Bender et al, 1994). Aberrantly migrating SSCP bands were excised and the DNA was extracted. After reamplification with the same set of primers, the PCR products were sequenced on a semiautomated sequencer (Applied Biosystems, model 310, Foster City, USA) using a Taq cycle sequencing kit (Abi Prism) dye terminator cycle sequencing ready reaction kit, Perkin Elmer, Alameda, USA).

Under the same conditions used here, we previously detected 32 mutations in brain tumours (Duerr et al, 1998). These mutations included deletions, insertions, missense and nonsense mutations in exons 1–8.

Analysis for homozygous deletions

A PCR assay for the detection of homozygous deletions has been described previously (Hayashi et al, 1997). In brief, a 160-bp fragment including exon 4 of the PTEN gene was coamplified with a 171-bp fragment from intron 7 of the DESMIN gene. Bands were detected by the semiautomatic sequencer Licor 4200 and analysed with the One-Dscan-Software. Significant differences between DESMIN and PTEN signal intensity were only observed for the DNA template of the glioblastoma cell line A172 lacking the Cowen critical region was used as a positive control (Li et al, 1997).

RESULTS

Mutation detection by SSCP and direct sequencing

The index patients of the 25 breast cancer families were examined for germline mutations in PTEN. BRCA1 mutations had previously been excluded. Five families were negative for BRCA2 mutations and an additional ten families were negative for frequent mutations in exons 9, 23 and 27. No abberant migration patterns of the PTEN SSCP fragments could be detected in any of these patients.

One of the 103 sporadic tumours showed an altered migration pattern. Sequence analysis revealed a 10-bp deletion within exon 8 resulting in a truncated protein with a stop signal at codon 343 in exon 9. This mutation was proven to be of somatic origin by analysis of constitutional DNA (Figure 1). No LOH could be observed in this tumour sample for the other allele. The tumour occurred in a 67-year-old woman and was histopathologically classified as an invasive ductal carcinoma, pT1c, pN0, pM0, WHO grade III, oestrogen and progesterone positive.

Homozygous deletions

Our tumour samples were also screened for homozygous deletions. Carcinoma samples with PTEN/DES ratios lower than mean minus 3 s.d., i.e. <0.97, were considered to have PTEN deletions in order to introduce a correction factor for the contamination of breast carcinoma tissue with stromal cells. Applying this calculation, none of the tumours showed evidence for a homozygous deletion of the PTEN gene (Figure 2).
PTEN mutations in breast cancer

Loss of heterozygosity

Analysis of three microsatellite markers in 92 informative carcinomas revealed ten tumours with LOH10q in at least one locus. However, only two carcinomas exhibited LOH including the entire Cowden critical region (Figure 3).

LOH analysis in other chromosomal regions revealed frequencies of 20% for the marker D17S855 (16 out of 79 informative tumours), 20% for the marker D13S267 (13 out of 68), 41% for the marker TP53 (13 out of 32) and 60% for the marker D16S539 (30 out of 51).

Microsatellite instability

To examine a potential association of PTEN mutations with microsatellite instability, four microsatellite markers located on different chromosomes were analysed in a panel of 11 carcinomas including ten carcinomas without PTEN mutations and the one tumour with a PTEN mutation. No evidence for microsatellite instability was observed with any of these markers.

DISCUSSION

Recent reports on mutations of the PTEN tumour-suppressor gene in Cowden disease and in a variety of different tumour entities have raised the possibility of an involvement of PTEN in breast carcinogenesis (Li et al, 1997; Liaw et al, 1997; Steck et al, 1997). We here present data of a PTEN mutational analysis in 103 sporadic breast carcinomas and 25 families afflicted with hereditary breast and ovarian cancer. The results strongly indicate that alterations of the PTEN gene are a rare event in breast carcinomas.

Analysis of PTEN in Cowden syndrome and early onset familial breast cancer also failed to detect germline mutations in this subset of breast cancer families (Tsou et al, 1997). Moreover, the authors of a recent report failed to detect any germline mutation in the PTEN gene in a set of 136 breast cancer families in which alterations of BRCA1, BRCA2, TP53 and ATM were previously excluded (Chen et al, 1998). Our analysis comprised families with breast and/or ovarian cancer not restricted to early onset of the disease. The absence of germline mutations in both studies implies that PTEN does not contribute significantly to the formation of hereditary breast and ovarian cancer. Rhei et al (1997) described a somatic 2-bp deletion and a 4-bp germline deletion in a series of 54 unselected primary breast cancers. Subsequent clinical examination attributed the germline deletion to a family history of Cowden syndrome. Ueda et al (1998) detected only one missense mutation in a series of 69 primary breast cancers. These data are in accordance with our results demonstrating that PTEN mutations are an infrequent event in primary sporadic breast cancer. Moreover, in contrast to initial results on breast cancer cell lines (Li et al, 1997), our findings indicate that homozygous deletions are uncommon in primary breast carcinomas.

In addition to the two mutations, Rhei et al (1997) identified several missense variants that occurred in most of the tumour samples. Recently, a highly conserved and processed PTEN pseudogene has been found on chromosomal band 9p21 (Bostroem et al, 1998; Dahia et al, 1998). This gene shares 98% sequence homology with the coding region of functional PTEN. Analysis of cDNA from a glioblastoma cell line with PTEN deletion suggests that the pseudogene is transcriptionally inactive. Nine of the 11 variants described by Rhei et al (1997) align with the pseudogene sequence. As this analysis was performed with a cDNA template, any of the mRNA variants may well represent a DNA pseudogene contamination of the mRNA samples. Alternatively, the pseudogene may be expressed in breast carcinoma. However, in our analysis of genomic DNA from 103 primary tumours, we could not detect any sequence variation.

The association of PTEN mutations in microsatellite instability-positive endometrial carcinomas (Tashiro et al, 1997) raised the possibility that PTEN may be associated with microsatellite instability. This property is also supported by the detection of microsatellite instability on chromosomal band 10q11–qter in primary breast carcinomas (Sourvinos et al, 1997). It was, therefore, of interest to analyse these tumours for microsatellite instability. However, our analysis with four microsatellite markers that represent frequent targets of replication error did not reveal microsatellite instability neither in the tumour sample exhibiting a PTEN mutation nor in ten breast carcinomas without mutant PTEN.

In contrast to the initial reports of high allelic loss rates in the PTEN region on chromosome 10q in 50% and 34% of primary breast carcinomas respectively (Li et al, 1997; Steck et al, 1997), our analysis revealed LOH10q23 in less than 10% of the tumours. No allelic loss was detected in the carcinoma carrying a PTEN mutation. This is in agreement with the observation of Kerangueven et al (1997), who also failed to identify a significant incidence of LOH10q in a panel of 115 breast carcinomas. However, the investigators of a recent report (Singh et al, 1998) could detect loss of heterozygosity close to the PTEN region in 9 out of 22 breast carcinomas. LOH10q23 in these tumour samples was associated with high-grade tumours. This is in accordance with Rasheed et al (1997), who suggested that in gliomas PTEN mutations are restricted to high-grade tumours. The low frequency of LOH10q23 in our tumour panel may be explained by the predominance of early stage tumours with a favourable prognosis. This is supported by the detection of significant LOH frequencies of 20–60% in other chromosomal regions frequently altered in early stage breast carcinomas.

In addition, we could not detect homozygous PTEN deletions in our primary breast carcinoma samples as reported by other groups (Li et al, 1997; Steck et al, 1997). To detect focal homozygous deletion, we have chosen to amplify exon 4 because the minimal region of loss occurred between exons 2 and 5 in tumour cell lines (Steck et al, 1997). It is, therefore, unlikely that we have missed a significant portion of homozygous deletions.
In summary, our findings suggest that PTEN does not play a major role in the pathogenesis of sporadic and hereditary breast cancer. It remains to be studied whether another, yet unidentified, tumour-suppressor gene on chromosome 10q participates in mammary carcinogenesis.

ACKNOWLEDGEMENT

We thank our colleagues Dr K Jäger, Dr P Citoler, Dr N Wernert for supplying tumour material and histopathological data. The excellent technical assistance by Eva-Maria Duerr and Birgit Meyer-Puttlitz is gratefully acknowledged. This study was supported by the Deutsche Forschungsgemeinschaft (Schm 800/2–3, 800/2–4), Deutsche Krebshilfe, BONFOR programme and the Schäffersnolte Foundation.

REFERENCES

Bender B, Wiestrzer OD and Von Deimling A (1994) A device for processing large acrylamide gels. Biotechniques 16: 204–207.

Bloom HJ and Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1049 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377.

Bocker T, Diermann J, Friedl W, Gebert J, Holinski-Feder E, Karner-Hanusch J, von Knebel-Docheritz M, Koeblee K, Moselein G, Schackert HK, Wirtz HC, Fishel R and Ruschoff J (1997) Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res 57: 4739–4743.

Bostroem J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP and Riffenberger G (1998) Mutation of the PTEN/MMAC1 tumour suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome 10q. Cancer Res 58: 29–33.

Chen J, Lindblom P and Lindblom A (1998) A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 102: 124–125.

Dahia LM, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Hulskus FG, Haber DA and Eng C (1998) A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 16: 2403–2406.

Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestrzer OD, Parsons R, Eng C and von Deimling A (1998) PTEN mutations in gliomas and glioneural tumours. Oncogene 15: 2254–2259.

Fearon ER (1997) Human cancer syndromes: clues to the origin and nature of cancer. Science 278: 1043–1050.

Guldberg P, hor Straten P, Birck A, Ahrenkli V, Kirkin AF and Zeuzhet J (1997) Disruption of the MMAC/Pten gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660–3663.

Hayashi Y, Ukiki K, Waha A, Wiester OD, Louis DN and von Deimling A (1997) Association of EGF gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871–875.

Kerangueven F, Eisinger F, Noguchi T, Allione F, Wargniez V, Engel C, Padberg G, Hayashi Y, Ueki K, Waha A, von Deimling A, Li J, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer (see comments). Science 275: 1943–1947.

Liaw D, Marsh DJ, Li J, Dahia PL, Wang S1, Zheng Z, Bose S, Call KM, Touc H, Peacocke M, Eng C and Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67.

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenblath J, Hussey C, Tran T, McClure M, Frye C, Hattler T, Phelps R, Hauenga-Anstra A, Kitchener H, Yakumo K, Gholami Z, Shaffer D, Stone S, Baye S, Wray C, Bogden R, Dayanathan P, Ward J, Tumik P, Naredo S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett C, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH (1994) A strong candidate gene for the breast and ovarian cancer susceptibility gene BRC1A.

Science 266: 66–71.

Miki Y, Katagiri T, Kusumi F, Yoshimoto T and Nakamura Y (1996) Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13: 245–247.

Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods MG, Mariman EC, Padberg GW and Kremer H (1997) Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6: 1383–1387.

Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Biggen DD and Bigner SH (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187–4190.

Remmele W, Hildebrandt U, Hienz PJ, Fierbuchmen B, Behmken L, Heuske B and Scheibel B (1986) Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barrett bodies in human cancer. Virchows Arch A Pathol Anat Histopathol 409: 127–147.

Rhei E, Kang L, Bogomolnyi LF, Federici MG, Borgen PI and Boyd J (1997) Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657–3659.

Schmutzler RK, Bierhoff E, Werkhausen T, Fimnners R, Speiser P, Kuhista E, Krebs D, Zeillinger R, Wiester OD and Von Deimling A (1997) Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast cancer. Int J Cancer 74: 322–325.

Singh B, Ittmann MM and Krolevski JJ (1998) Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21: 166–171.

Sourvinos G, Kiarios H, Tiiskinins A, Vassilarios S and Spandidos DA (1997) Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol 18: 157–166.

Spesell B, Behars OB and Hermane P (1990) UICC TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. Springer Verlag: Berlin.

Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Schwedhun B, Teng DH and Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Cancer Res 57: 4183–4186.

Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SL, Li J, Parsons R and Ellenher L (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935–3940.

Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, Xie XK, Gruener AC, Schrager CA, Christiano AM, Eng C, Steck P, Ott J, Tavtigian SV and Peacocke M (1997) The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases (in process citation). Am J Hum Genet 61: 1036–1043.

Ueda K, Nishijima M, Inui H, Watatani M, Yayoi E, Okamura J, Yasutomi M, Nakamura Y and Miyoshi Y (1998) Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res 89: 17–21.

von Deimling A, Bender B, Louis DN and Wiester OD (1993) A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neoplasia Appl Neuropathol 19: 524–529.

Wang SL, Puc J, Li J, Bruce JN, Cairns P, Sidransky D and Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183–4186.

Wiester R, Bignell G, Lancaster J, Swift S, Seal S, Mangan J, Collins N, Gregory S, Gumbs C and Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA1 (see comments) (published erratum appears in Nature 1996, 379, 749). Nature 379: 789–792.

World Health Organization (1981) Histological Typing of Breast Tumours. 2nd Edition. International Classification of Tumors. World Health Organization: Geneva.